Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Effects of total flavonoids from Drynariae Rhizoma prevent bone loss in vivo and in vitro.

Song SH, Zhai YK, Li CQ, Yu Q, Lu Y, Zhang Y, Hua WP, Wang ZZ, Shang P.

Bone Rep. 2016 Sep 10;5:262-273. doi: 10.1016/j.bonr.2016.09.001. eCollection 2016 Dec.

2.

Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives.

Kuo TR, Chen CH.

Biomark Res. 2017 May 18;5:18. doi: 10.1186/s40364-017-0097-4. eCollection 2017. Review.

3.

The association of time and medications with changes in bone mineral density in the 2 years after critical illness.

Orford NR, Bailey M, Bellomo R, Pasco JA, Cattigan C, Elderkin T, Brennan-Olsen SL, Cooper DJ, Kotowicz MA.

Crit Care. 2017 Mar 21;21(1):69. doi: 10.1186/s13054-017-1657-6.

4.

Metabolomics and Its Application in the Development of Discovering Biomarkers for Osteoporosis Research.

Lv H, Jiang F, Guan D, Lu C, Guo B, Chan C, Peng S, Liu B, Guo W, Zhu H, Xu X, Lu A, Zhang G.

Int J Mol Sci. 2016 Dec 2;17(12). pii: E2018. Review.

5.

Risk factors for osteoporosis in patients with end-stage liver disease.

Uchida S, Miyaaki H, Ichikawa T, Taura N, Miuma S, Honda T, Shibata H, Haraguchi M, Senoo T, Nakao K.

Biomed Rep. 2016 Nov;5(5):629-633. Epub 2016 Sep 29.

6.

Serum sclerostin decreases following 12months of resistance- or jump-training in men with low bone mass.

Hinton PS, Nigh P, Thyfault J.

Bone. 2017 Mar;96:85-90. doi: 10.1016/j.bone.2016.10.011. Epub 2016 Oct 12.

PMID:
27744012
7.

Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial.

Graff IE, Øyen J, Kjellevold M, Frøyland L, Gjesdal CG, Almås B, Rosenlund G, Lie Ø.

Oncotarget. 2016 Oct 25;7(43):69200-69215. doi: 10.18632/oncotarget.10171.

8.

Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis.

Vaculík J, Braun M, Dungl P, Pavelka K, Stepan JJ.

BMC Musculoskelet Disord. 2016 Jul 22;17:308. doi: 10.1186/s12891-016-1168-7.

9.

Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing's syndrome.

Belaya ZE, Iljin AV, Melnichenko GA, Solodovnikov AG, Rozhinskaya LY, Dzeranova LK, Dedov II.

Bonekey Rep. 2016 Jun 15;5:815. doi: 10.1038/bonekey.2016.42. eCollection 2016.

10.

Dysregulation of ossification-related miRNAs in circulating osteogenic progenitor cells obtained from patients with aortic stenosis.

Takahashi K, Satoh M, Takahashi Y, Osaki T, Nasu T, Tamada M, Okabayashi H, Nakamura M, Morino Y.

Clin Sci (Lond). 2016 Jul 1;130(13):1115-24. doi: 10.1042/CS20160094. Epub 2016 Apr 14.

11.

Teriparatide for osteoporosis: importance of the full course.

Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ.

Osteoporos Int. 2016 Aug;27(8):2395-410. doi: 10.1007/s00198-016-3534-6. Epub 2016 Feb 22. Review.

12.

Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population.

Dai Z, Wang R, Ang LW, Yuan JM, Koh WP.

Bone. 2016 Feb;83:171-7. doi: 10.1016/j.bone.2015.11.005. Epub 2015 Nov 7.

13.

Effect of weight loss on bone health in overweight/obese postmenopausal breast cancer survivors.

Toriola AT, Liu J, Ganz PA, Colditz GA, Yang L, Izadi S, Naughton MJ, Schwartz AL, Wolin KY.

Breast Cancer Res Treat. 2015 Aug;152(3):637-43. doi: 10.1007/s10549-015-3496-y. Epub 2015 Jul 15.

14.

Effects of OsteoKing on osteoporotic rabbits.

Dai L, Wu H, Yu S, Zhao H, Xue L, Xu M, Shen Z, Hu M.

Mol Med Rep. 2015 Jul;12(1):1066-74. doi: 10.3892/mmr.2015.3551. Epub 2015 Mar 26.

15.

Harmonised Australian Reference Intervals for Serum PINP and CTX in Adults.

Vasikaran SD, Chubb SP, Ebeling PR, Jenkins N, Jones GR, Kotowicz MA, Morris HA, Schneider HG, Seibel MJ, Ward G.

Clin Biochem Rev. 2014 Nov;35(4):237-42. Review.

16.

Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis.

Abboskhujaeva LS, Ismailov SI, Alikhanova NM.

Drugs R D. 2014 Dec;14(4):315-24. doi: 10.1007/s40268-014-0069-1.

17.

Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.

Bonjour JP, Kohrt W, Levasseur R, Warren M, Whiting S, Kraenzlin M.

Nutr Res Rev. 2014 Dec;27(2):252-67. doi: 10.1017/S0954422414000183. Epub 2014 Nov 14. Review.

18.

Ethnic differences in urinary calcium and phosphate excretion between Gambian and British older adults.

Redmond J, Palla L, Yan L, Jarjou LM, Prentice A, Schoenmakers I.

Osteoporos Int. 2015 Mar;26(3):1125-35. doi: 10.1007/s00198-014-2926-8. Epub 2014 Oct 14.

19.

Cathepsin K in treatment monitoring following intravenous zoledronic acid.

Jahn O, Wex T, Klose S, Kropf S, Adolf D, Piatek S.

Biomed Rep. 2014 Nov;2(6):915-917. Epub 2014 Sep 10.

20.

Bone mineral density in residents of care facilities for the aged and effect of pharmacotherapy.

Tokuda T, Hasegawa J, Matsuda A, Hagino H.

Yonago Acta Med. 2014 Mar;57(1):45-52. Epub 2014 Apr 28.

Supplemental Content

Support Center